Drugs / IDV184001AN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05974046 | Jul 2023 | substance-related disorder | Indivior Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDV184001AN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05974046 ↗ |
| Route | Oral | “Oral administration of IDV184001AN” NCT05974046 ↗ |